ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens

MLA

Maria Pihlgren, et al. “ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens.” Blood, vol. 140, Nov. 2022, pp. 858–59. EBSCOhost, https://doi.org/10.1182/blood-2022-159353.

APA

Maria Pihlgren, Olivia Hall, Laura Carretero, Carole Estoppey, Adam Drake, Daniela Pais, Jeremy Loyau, Jeremy Berret, Isabelle Gruber, Perrine Suere, Vincent Schnorhk, Emilie Nallet, Blandine Pouleau, Myriam Chimen, Julie Macoin, Elodie Stainnack, Thierry Monney, Aurore Delachat, Cyrille Dreyfus, … Mario Perro. (2022). ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens. Blood, 140, 858–859. https://doi.org/10.1182/blood-2022-159353

Chicago

Maria Pihlgren, Olivia Hall, Laura Carretero, Carole Estoppey, Adam Drake, Daniela Pais, Jeremy Loyau, et al. 2022. “ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens.” Blood 140 (November): 858–59. doi:10.1182/blood-2022-159353.